Eli Lilly has announced new data on its once-weekly, injectable glucagon-like peptide Trulicity (dulaglutide 1.5mg) and investigational 3.0 and 4.5mg doses of dulaglutide, revealing that all three provided “significantly better blood sugar control with weight benefits” in the treatment of type 2 diabetes compared to placebo.
Reageer